This document provides expert recommendations and a contemporary strategy for managing pediatric pulmonary hypertension, integrating recent trial data and European guidelines for Russian clinical practice.
Answers are grounded in this paper and cite their sources.
Supports targeted endothelin and nitric oxide pathway agents in pediatric PH; leaves open optimal combinations and long-term RCTs.
Pulmonary hypertension (PH) in pediatrics is a polygenic multifactorial condition with extremely adverse prognosis. Selection of optimal management is a severe task. In absence of treatment the mean life duration in children is not higher one year. Last two decades, revolution in approaches to treatment improved the survival of this patients group. Recently, pediatricians and pediatric cardiologists have three drugs groups that act on the main pathogenetic chains of PH: endothelin pathway, nitric oxide pathway and prostacyclin pathway. At the moment, approaches to pediatric PH are based on the data obtained in the trials on adult patients. However, not long ago there were first randomized trials on children performed. The group of authors of current article presents a modern view on the problem of PH in children, and expert recommendations on children management. Class of recommendations and evidence level were set by the data obtained in pediatric population or on adult population with at least 10% of children included. To the strategy, developed by the Russian clinicians, laid the analysis of experience of the pathology treatment in Russian Federation, as the current practics and clinical guidelines on pediatric PH in Europe, and the recent trials published.
No takes yet. Share an insight, caveat, or question.
Миклашевич et al. (2018) conducted a review in Pediatric pulmonary hypertension. Pulmonary hypertension management strategies was evaluated. Contemporary management strategies for pediatric pulmonary hypertension, including endothelin, nitric oxide, and prostacyclin pathway drugs, improve survival beyond the historical 1-year expectancy.
Synapse has enriched 10 related papers. Consider them for comparative context: